{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:27:09Z","timestamp":1793330829942,"version":"4.5.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1053\/j.gastro.2022.08.045","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:19:16Z","timestamp":1666243156000},"page":"1198-1225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":346,"title":["AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity"],"prefix":"10.1053","volume":"163","author":[{"given":"Eduardo","family":"Grunvald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Hernaez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva Krishna","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavia","family":"Pickett-Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi M.","family":"Teigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasma","family":"Harindhanavudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perica","family":"Davitkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.08.045_bib1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999\u20132000","volume":"288","author":"Flegal","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib2","doi-asserted-by":"crossref","unstructured":"Stierman B, Afful J, Carroll MD, et\u00a0al. National Health and Nutrition Examination Survey 2017\u2013March 2020 Prepandemic Data Files Development of Files and Prevalence Estimates for Selected Health Outcomes. National Center for Health Statistics. Published June 14, 2021. Available at: https:\/\/doi.org\/10.15620\/cdc:106273. Accessed August 28, 2022.","DOI":"10.15620\/cdc:106273"},{"key":"10.1053\/j.gastro.2022.08.045_bib3","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.2021.16685","article-title":"Trends in obesity prevalence among adults aged 18 through 25 years, 1976-2018","volume":"326","author":"Ellison-Barnes","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.gastro.2022.08.045_bib4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053708","article-title":"Changes in the incidence of childhood obesity","volume":"150","author":"Cunningham","year":"2022","journal-title":"Pediatrics"},{"key":"10.1053\/j.gastro.2022.08.045_bib5","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2022.08.045_bib6","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/oby.22581","article-title":"Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015","volume":"27","author":"Saxon","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1053\/j.gastro.2021.03.003","article-title":"AGA clinical practice guidelines on intragastric balloons in the management of obesity","volume":"160","author":"Muniraj","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.08.045_bib8","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1053\/j.gastro.2021.02.043","article-title":"AGA technical review on intragastric balloons in the management of obesity","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.08.045_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA Institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.08.045_bib10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2022.08.045_bib11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/dom.14133","article-title":"Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome","volume":"22","author":"Haws","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1053\/j.gastro.2022.08.045_bib13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029966","article-title":"Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials","volume":"9","author":"Singh","year":"2019","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2022.08.045_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cgh.2016.10.023","article-title":"White paper AGA: POWER - practice guide on obesity and weight management, education, and resources","volume":"15","author":"Acosta","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2022.08.045_bib17","first-page":"211s","article-title":"Effect of degree of weight loss on health benefits","volume":"3","author":"Blackburn","year":"1995","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2022.08.045_bib18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/oby.21358","article-title":"Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?","volume":"23","author":"Williamson","year":"2015","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2022.08.045_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2022.08.045_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2022"},{"key":"10.1053\/j.gastro.2022.08.045_bib23","series-title":"Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice","article-title":"Fixed-effects and random-effects models","author":"Murad","year":"2015"},{"key":"10.1053\/j.gastro.2022.08.045_bib24","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2022.08.045_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1053\/j.gastro.2022.08.045_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/osp4.390","article-title":"The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity","volume":"6","author":"Lee","year":"2020","journal-title":"Obes Sci Pract"},{"key":"10.1053\/j.gastro.2022.08.045_bib27","first-page":"1096","article-title":"Ten-year Medicare budget impact of increased coverage for anti-obesity intervention","volume":"22","author":"Chen","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1053\/j.gastro.2022.08.045_bib28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib29","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2022.08.045_bib31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1053\/j.gastro.2022.08.045_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib38","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"10.1053\/j.gastro.2022.08.045_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/oby.22359","article-title":"Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial","volume":"27","author":"Wadden","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib43","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2022.08.045_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib45","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2022.08.045_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib48","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2022.08.045_bib50","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/dom.14367","article-title":"Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States","volume":"23","author":"Suissa","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib51","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib52","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib53","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0310057X0503300418","article-title":"Phentermine and anaesthesia","volume":"33","author":"Stephens","year":"2005","journal-title":"Anaesth Intensive Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/SAP.0000000000001478","article-title":"Phentermine: a systematic review for plastic and reconstructive surgeons","volume":"81","author":"Lim","year":"2018","journal-title":"Ann Plast Surg"},{"key":"10.1053\/j.gastro.2022.08.045_bib58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.gastro.2022.08.045_bib59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2022.08.045_bib60","series-title":"Encyclopedia of Endocrine Diseases","first-page":"464","article-title":"Treatment: new drugs","author":"Garelli","year":"2019"},{"key":"10.1053\/j.gastro.2022.08.045_bib61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A\u00a06-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2022.08.045_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00228-006-0220-1","article-title":"The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension","volume":"63","author":"Tremblay","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2022.08.045_bib63","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","article-title":"Influence of topiramate in the regulation of energy balance","volume":"16","author":"Richard","year":"2000","journal-title":"Nutrition"},{"key":"10.1053\/j.gastro.2022.08.045_bib64","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.ijo.0801873","article-title":"The effects of topiramate and sex hormones on energy balance of male and female rats","volume":"26","author":"Richard","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib65","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1463-1326.2006.00618.x","article-title":"Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes","volume":"9","author":"Stenl\u00f6f","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.ijo.0803382","article-title":"Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"31","author":"Toplak","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2022.08.045_bib67","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","article-title":"Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension","volume":"96","author":"Tonstad","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.gastro.2022.08.045_bib68","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects","volume":"28","author":"Wilding","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1389-9457(03)00060-1","article-title":"Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate","volume":"4","author":"Winkelman","year":"2003","journal-title":"Sleep Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib70","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.4088\/JCP.v67n1109","article-title":"Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series","volume":"67","author":"Winkelman","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1053\/j.gastro.2022.08.045_bib71","first-page":"276","article-title":"[Nocturnal sleep-related eating disorder that responds to topiramate]","volume":"45","author":"Martinez-Salio","year":"2007","journal-title":"Rev Neurol"},{"key":"10.1053\/j.gastro.2022.08.045_bib72","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/2013.jamainternmed.99","article-title":"Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial","volume":"172","author":"Gadde","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib73","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.v68n0809","article-title":"Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study","volume":"68","author":"Gadde","year":"2007","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1053\/j.gastro.2022.08.045_bib74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5414\/CP203943","article-title":"Three- and six-month efficacy and safety of phentermine in a Mexican obese population","volume":"59","author":"M\u00e1rquez-Cruz","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib76","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2012.07.008","article-title":"Use of topiramate in pregnancy and risk of oral clefts","volume":"207","author":"Margulis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.gastro.2022.08.045_bib78","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00240-010-0347-5","article-title":"Nephrolithiasis in topiramate users","volume":"39","author":"Maalouf","year":"2011","journal-title":"Urol Res"},{"key":"10.1053\/j.gastro.2022.08.045_bib79","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib80","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib81","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A\u00a0randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib83","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib85","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib87","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0149-7634(02)00041-6","article-title":"Opioid peptides and the control of human ingestive behaviour","volume":"26","author":"Yeomans","year":"2002","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1053\/j.gastro.2022.08.045_bib88","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib89","first-page":"256","article-title":"Seizures and bupropion: a review","volume":"50","author":"Davidson","year":"1989","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1053\/j.gastro.2022.08.045_bib90","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0006-3223(01)01317-8","article-title":"Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression","volume":"51","author":"Weihs","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1053\/j.gastro.2022.08.045_bib91","article-title":"Naltrexone\/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study","volume":"15","author":"McElroy","year":"2013","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib92","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1742-1241.2003.tb10468.x","article-title":"Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience","volume":"57","author":"Ferry","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.gastro.2022.08.045_bib93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.addbeh.2009.10.017","article-title":"An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects","volume":"35","author":"Wilcox","year":"2010","journal-title":"Addict Behav"},{"key":"10.1053\/j.gastro.2022.08.045_bib94","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cpt.402","article-title":"Bupropion and naltrexone for smoking cessation: a double-blind randomized placebo-controlled clinical trial","volume":"100","author":"Mooney","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib95","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2147\/DMSO.S311359","article-title":"Cardiovascular safety and superiority of anti-obesity medications","volume":"14","author":"Alobaida","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1053\/j.gastro.2022.08.045_bib96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","article-title":"A\u00a0randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin","volume":"22","author":"Berne","year":"2005","journal-title":"Diabet Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib97","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1053\/j.gastro.2022.08.045_bib98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib99","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","article-title":"The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"4","author":"Hanefeld","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib101","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib102","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"10.1053\/j.gastro.2022.08.045_bib103","first-page":"S24","article-title":"A\u00a0one-year trial to assess the value of orlistat in the management of obesity","volume":"21","author":"James","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib104","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.ijo.0802281","article-title":"Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity","volume":"27","author":"Krempf","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1053\/j.gastro.2022.08.045_bib106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study","volume":"248","author":"Lindg\u00e4rde","year":"2000","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib107","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib108","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0002-9149(00)01521-6","article-title":"Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X","volume":"87","author":"Reaven","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.gastro.2022.08.045_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","journal-title":"Obes Res"},{"key":"10.1053\/j.gastro.2022.08.045_bib110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.08.045_bib111","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"J\u00a0Hypertens"},{"key":"10.1053\/j.gastro.2022.08.045_bib112","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2796.2006.01702.x","article-title":"Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat","volume":"260","author":"Poston","year":"2006","journal-title":"J\u00a0Intern Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc06-0210","article-title":"Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study","volume":"30","author":"Richelsen","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib116","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","article-title":"Effect of orlistat on cardiovascular disease risk in obese adults","volume":"7","author":"Swinburn","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib117","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1517\/14656566.2010.493557","article-title":"Comparison of orlistat treatment and placebo in obese type 2 diabetic patients","volume":"11","author":"Derosa","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.gastro.2022.08.045_bib118","series-title":"Xenical [orlistat]. Package insert","year":"2012"},{"key":"10.1053\/j.gastro.2022.08.045_bib120","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib121","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short-term phentermine administration in Korean obese people","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med J"},{"key":"10.1053\/j.gastro.2022.08.045_bib122","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2022.08.045_bib123","first-page":"251","article-title":"A\u00a0pilot randomized trial comparing a commercial weight loss program with a clinic-based intervention for weight loss","volume":"3","author":"Tsai","year":"2012","journal-title":"J\u00a0Prim Care Community Health"},{"key":"10.1053\/j.gastro.2022.08.045_bib124","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"key":"10.1053\/j.gastro.2022.08.045_bib125","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib126","first-page":"289","article-title":"A\u00a0double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity","volume":"16","author":"Langlois","year":"1974","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1053\/j.gastro.2022.08.045_bib127","first-page":"155","article-title":"Double-blind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients","volume":"14","author":"Choi","year":"2005","journal-title":"Korean J Obes"},{"key":"10.1053\/j.gastro.2022.08.045_bib128","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/oby.21533","article-title":"Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s","volume":"24","author":"Thomas","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib129","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","article-title":"Pharmacotherapy for obesity-trends using a population level national database","volume":"31","author":"Elangovan","year":"2021","journal-title":"Obes Surg"},{"key":"10.1053\/j.gastro.2022.08.045_bib130","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.gastro.2022.08.045_bib131","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib132","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1517\/14740338.4.6.1083","article-title":"Safety of obesity drugs","volume":"4","author":"Greenway","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.gastro.2022.08.045_bib133","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease--it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib134","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1378\/chest.117.3.870","article-title":"Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension","volume":"117","author":"Rich","year":"2000","journal-title":"Chest"},{"key":"10.1053\/j.gastro.2022.08.045_bib135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","article-title":"Obesity pharmacotherapy","volume":"102","author":"Saunders","year":"2018","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.gastro.2022.08.045_bib136","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ijo.2009.124","article-title":"A\u00a0randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects","volume":"33","author":"Cercato","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2022.08.045_bib137","first-page":"437","article-title":"Clinical assessment of the use of an anorectic drug in a total weight reduction program","volume":"17","author":"McQuarrie","year":"1975","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1053\/j.gastro.2022.08.045_bib138","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/ijo.2013.225","article-title":"A\u00a0comparative study of five centrally acting drugs on the pharmacological treatment of obesity","volume":"38","author":"Suplicy","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2022.08.045_bib139","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5414\/CP202135","article-title":"Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial","volume":"53","author":"Soto-Molina","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib140","first-page":"329","article-title":"Controlled-release diethylpropion hydrochloride used in a program for weight reduction","volume":"3","author":"Parsons","year":"1981","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2022.08.045_bib141","first-page":"234","article-title":"An evaluation of behavioral techniques reinforced with an anorectic drug in a double-blind weight loss study","volume":"41","author":"Abramson","year":"1980","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1053\/j.gastro.2022.08.045_bib142","series-title":"FDA Adverse Events Reporting System (FAERS) Public Dashboard - FDA Adverse Events Reporting System (FAERS) Public Dashboard. Sheet. Qlik Sense","year":"2022"},{"key":"10.1053\/j.gastro.2022.08.045_bib143","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","article-title":"Anorectics on trial: a half century of federal regulation of prescription appetite suppressants","volume":"143","author":"Colman","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib144","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11695-014-1466-9","article-title":"How physician obesity medicine specialists treated obesity before 2012 new drug approvals","volume":"25","author":"Schmidt","year":"2015","journal-title":"Obes Surg"},{"key":"10.1053\/j.gastro.2022.08.045_bib146","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib148","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1037\/0022-006X.65.1.79","article-title":"What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes","volume":"65","author":"Foster","year":"1997","journal-title":"J\u00a0Consult Clin Psychol"},{"key":"10.1053\/j.gastro.2022.08.045_bib150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s13679-016-0211-1","article-title":"Disparities in treatment uptake and outcomes of patients with obesity in the USA","volume":"5","author":"Lewis","year":"2016","journal-title":"Curr Obes Rep"},{"key":"10.1053\/j.gastro.2022.08.045_bib151","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s13679-018-0301-3","article-title":"Racial disparities in obesity treatment","volume":"7","author":"Byrd","year":"2018","journal-title":"Curr Obes Rep"},{"key":"10.1053\/j.gastro.2022.08.045_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221090009","article-title":"Anti-obesity medication prescriptions by race\/ethnicity and use of an interpreter in a pediatric weight management clinic","volume":"13","author":"Bomberg","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib153","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMe2025728","article-title":"Addressing disparities in the management of obesity in primary care settings","volume":"383","author":"Wadden","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib154","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S2213-8587(21)00081-4","article-title":"Semaglutide for obesity: four STEPs forward, but more to come","volume":"9","author":"Ryan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2022.08.045_bib156","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib157","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/oby.23120","article-title":"Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic","volume":"29","author":"Acosta","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib158","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/oby.23068","article-title":"Pharmacogenomics of medication-induced weight gain and antiobesity medications","volume":"29","author":"Singh","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2022.08.045_bib159","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1517\/14656560902824152","article-title":"Combination pharmaceutical therapies for obesity","volume":"10","author":"Gadde","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.gastro.2022.08.045_bib160","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ph3082398","article-title":"Combinations of drugs in the treatment of obesity","volume":"3","author":"Halpern","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.gastro.2022.08.045_bib161","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13679-021-00425-1","article-title":"Use of weight loss medications in patients after bariatric surgery","volume":"10","author":"Redmond","year":"2021","journal-title":"Curr Obes Rep"},{"key":"10.1053\/j.gastro.2022.08.045_bib162","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1319-3767.203362","article-title":"Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?","volume":"23","author":"Mosli","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.08.045_bib163","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s11695-020-05117-8","article-title":"Efficacy of liraglutide to prevent weight regain after retrieval of an adjustable intra-gastric balloon-a case-matched study","volume":"31","author":"Badurdeen","year":"2021","journal-title":"Obes Surg"},{"key":"10.1053\/j.gastro.2022.08.045_bib164","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2022.08.045_bib166","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.1053\/j.gastro.2022.08.045_bib167","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.2018.13022","article-title":"Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force Recommendation Statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2022.08.045_bib168","author":"McKinney"},{"issue":"Suppl 3","key":"10.1053\/j.gastro.2022.08.045_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College Of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients With Obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2022.08.045_bib170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2022.08.045_bib171","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Cmaj"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522010265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522010265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:37:30Z","timestamp":1758037050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522010265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":166,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0016508522010265"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}